OPG and RANKL in Breast Cancer Research

Breast Cancer Awareness Month –  OPG and RANKL Research

October marks Breast Cancer Awareness Month, a time to raise awareness and highlight scientific advances that deepen our understanding of breast cancer progression. Although early detection and treatment remain central to improving outcomes, ongoing research continues to uncover the biological pathways that influence how breast cancer develops, spreads, and interacts with the body.

One area of particular importance is bone metastasis. The bone marrow is a frequent site of breast cancer metastasis and contributes substantially to patient morbidity and mortality worldwide. Understanding the processes that support or limit tumor spread to bone is therefore critical for advancing translational cancer research and identifying potential biomarkers that may help improve patient monitoring and therapeutic strategies.

OPG and RANKL in Breast Cancer Research

A recent publication, “OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. highlights the OPG/RANKL axis as an important immune-related pathway in breast cancer bone metastasis. Based on data from a preclinical model, the study explores how specific immune cell populations may be associated with different patterns of metastatic risk in bone.

Key insights from the publication include:

• OPG-producing B cells were associated with reduced bone metastatic burden
• RANKL-expressing T cells were linked to increased metastatic risk
• The OPG/RANKL pathway remains highly relevant in bone biology, osteoimmunology, and translational cancer research

 

OPG (Osteoprotegerin)  and RANKL (Receptor Activator of NF-κB Ligand) are well-established regulators of bone remodeling, with important roles in the communication between immune cells and the skeletal system. Their relevance in the context of breast cancer bone metastasis underscores the importance of reliable biomarker measurement tools for researchers investigating tumor–bone interactions and immune-mediated mechanisms.

At Biomedica, we support researchers studying these pathways with human OPG and RANKL ELISA assay kits designed for the measurement of these biomarkers in human samples. These tools can help advance research in bone metabolism, osteoimmunology, oncology, and related fields.

During Breast Cancer Awareness Month, we recognize the importance of continued scientific progress and the researchers working to improve our understanding of breast cancer biology (1-4).

Both Osteoprotegerin (OPG and soluble RANKL  can easily be measured with a conventional ELISA assay.

 Biomedica OPG ELISA (cat. no. BI-20403)

• Method: Sandwich ELISA, HRP/TMB, 12×8-well detachable strips
• Sample: Serum, plasma (EDTA, citrate, heparin)
• Sample volume: 20μl / well
• Detection range: 1.25-20 pmol/L (= 25 – 400 pg/mL)
• Sensitivity: 0.07 pmol/L (= 1.4 pg/mL)
• Incubation time: 4 h + 1 h + 30 min (room temperature)
• Precision: In-between-run (n=12): ≤ 5 % CV: Within-run (n=5): ≤ 3 % CV
• Widely cited in over 285 publications

 

Biomedica free soluble RANKL ELISA (cat. no. BI-20462) 

• Method: Sandwich ELISA, HRP/TMB, 12×8-well detachable strips
• Sample type: Serum, heparın plasma
• Sample volume: 150 µl / well
• Assay time: 2 h / overnight / 1 h / 30 min
• Sensitivity: 0.01 pmol/l (= 0.2 pg/ml)
• Standard range: 0 – 2 pmol/l (= 0 – 40 pg/ml)
• Conversion factor:: 1 pmol/l = 20 pg/ml (MW: 20 kDa; monomer)
• Precision: In-between-run (n=12): ≤ 3 % CV; Within-run (n=5): ≤ 5 % CV
• Widely cited in over 335 publications

– Extensively validated ELISA assays following international quality guidelines

– High Quality ELISA kits – Developed & Manufactured by Biomedica

Related ELISA kits:  DKK-1, Sclerostin, IL-6

 

 

Literature:

1. OPG-Producing B Cells and RANKL-Expressing T Cells Define Immune Signatures Predictive of Bone Metastases in Breast Cancer. Monteiro AC, Garcia DD, Fontão APA, Du Rocher B, Globa Masset ME, Alves IN, Carvalho LG, Andrade CV, Fidalgo G, Colaço MV, Nogueira LP, Dias Gaui MF, Bonomo A. Cancer Res Commun. 2026 Jan 1;6(1):85-104. doi: 10.1158/2.
2. The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer. De Leon-Oliva D, Barrena-Blázquez S, Jiménez-Álvarez L, Fraile-Martinez O, García-Montero C, López-González L, Torres-Carranza D, García-Puente LM, Carranza ST, Álvarez-Mon MÁ, Álvarez-Mon M, Diaz R, Ortega MA. Medicina (Kaunas). 2023 Sep 30;59(10):1752. doi: 10.3390/medicina59101752. PMID: 37893470; PMCID: PMC10608105.
3. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. J Exp Clin Cancer Res. 2019 Jan 8;38(1):12. doi: 10.1186/s13046-018-1001-2. PMID: 30621730; PMCID: PMC6325760.
4. The roles of osteoprotegerin in cancer, far beyond a bone player. Wang Y, Liu Y, Huang Z, Chen X, Zhang B. Cell Death Discov. 2022 May 6;8(1):252. doi: 10.1038/s41420-022-01042-0. PMID: 35523775; PMCID: PMC9076607.

 

Breast Cancer Awareness Month 2026 – related websites:

WHO – Breast Cancer Awareness Month 2026

Breast Cancer Org

Breast Cancer Now UK